Chief Medical Officer

Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases

Spyre Therapeutics announces first patient dosed in Phase 3 SKYWAY trial

Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

Spyre Therapeutics reports Q2 EPS (49c), consensus (71c)

Senior Manager, CMC Regulatory Affairs

Spyre Therapeutics is a clinical-stage biotechnology company focused on developing innovative products for inflammatory bowel disease and other immune-mediated diseases. The Senior Manager, Regulatory Affairs (CMC) will be responsible for managing CMC regulatory submissions and strategies, ensuring compliance with regulatory requirements, and collaborating with various teams to support clinical trials.

Sign up with Google

Sign in with Google